Friday, November 26, 2010

b

Polymorphic Pharmaceutical Compounds
Introduction:
The chemical industrial development in pharmaceutical industry is faced with the acceleration of the development time of new medicines and with harmonization guidelines which are required by health authorities for worldwide registration. Polymorphism is the ability of a substance to crystallize into different crystalline forms. These crystalline forms are called polymorphs or crystalline modifications. Polymorphs have the same liquid or gaseous state but they behave differently in the solid-state. The amorphous state is characterized by solidification in a disordered, random manner, structurally similar to the liquid-state. The expression pseudo-polymorphism applies to hydrates and solvates. These three types of solid phases are considered under the term ‘polymorphic behavior’ in this article. Review articles about polymorphism and relevance. Intrinsic properties of a new drug substance candidate are its pKa, its lipophilicity expressed by logP and its intrinsic chemical stability in solutions. Poor physical properties of substances may be changed by using the salt formation in case of acidic or basic compounds and by considering different polymorphs. Formulations are developed to improve solid-state properties and in certain cases affect the solid-state of the drug substance in the drug product. The ‘polymorphic’ behavior of organic substances is driven by thermodynamic and kinetic factors. Therefore several solid phases can coexist. Since the properties of the solid-state may be extremely relevant for the quality of drug products, the International Conference for Harmonization requires a polymorphic study of each new active ingredient with a three-step decision tree starting with detection of different solid phases, followed by the characterization of the different solid phases and if the properties are relevant for the drug product quantitative methods and specifications have to be developed for the drug substance and even for the drug product.

The most relevant property for health authorities is the bioavailability and the bioequivalence of formulation not always correlated with polymorphism, the stability and the robustness of the processes. The processing of the drug substances and drug products involve solvent, temperature and pressure changes as well as mechanical stress and different solid phases may coexist in the drug product. Organic substances show supersaturation behavior and unstable solid phases which should not exist in defined temperature, pressure and humidity may behave like stable forms. These solid metastable phases obtained outside their domains of stability will convert into the thermodynamic stable forms at given temperatures, pressures and relative humidities. These conversions driven by thermodynamic are governed by kinetic and are influenced by impurities, particle size, crystal defects, and presence of seeds. Design of the solid-state is the best choice of the salt candidate and the polymorphic form as early as possible in order to avoid delays due to new development, bioequivalence studies and upscale has to be taken into consideration since synthetic processes will be optimized from the first mg material to the production amount in tons range. For this challenging task, new technologies are now available: high throughput instrumentation, chemometrics, laboratory automation, in line or on line in process analytic have been added to the established high sophisticated technologies such as thermal analysis and calorimetry, X-ray diffraction, spectroscopy and combined techniques. On the other side, predictive computer tools are also available and the two approaches pushed academia and industry to apply better models and better tools in terms of precision and accuracy. Precise knowledge of thermodynamic stability and relationships between different solid phases is a pre-requisite for the manufacture of robust drug substance and drug products. It is also necessary to know the equilibration curves between the solid forms under the influence of the parameters humidity, temperature and pressure in order to predict changes for storage, stability, compatibility and pharmaceutical processes. The major hurdle for the pharmaceutical industry is to have to recall medicines because of polymorphism problems as it was the case for Ritonavir. Strategic development for both salt form and polymorphism are also reviewed. The sensitive quantification methods are needed for the development and are also now required for the monitoring of undesirable solid form(s).

Chemistry, manufacturing, and controls information must be submitted to support the approval of an abbreviated new drug application. This guidance is intended to assist applicants with the submission of ANDAs when a drug substance exists in polymorphic forms. Specifically, this guidance provides:
• FDA recommendations on assessing sameness when the drug substance exists in polymorphic forms.

Decision trees that provide recommendations on monitoring and controlling polymorphs and drug substances and/or drug products.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. DEFINITION OF TERMS: POLYMORPHIC FORMS AND POLYMORPHISM
We recommend that ANDA applicants investigate whether the drug substance in question can exist in polymorphic forms. Polymorphic forms in the context of this guidance refer to crystalline and amorphous forms as well as solvate and hydrate forms, which are described below.
• Crystalline forms have different arrangements and/or conformations of the molecules in the crystal lattice.

• Amorphous forms consist of disordered arrangements of molecules that do not possess a distinguishable crystal lattice.

• Solvates are crystal forms containing either stoichiometric or nonstoichiometric amounts of a solvent. If the incorporated solvent is water, the solvate is commonly known as a hydrate.

When a drug substance exists in polymorphic forms, it is said to exhibit polymorphism.

III. GENERAL PRINCIPLES OF PHARMACEUTICAL SOLID POLYMORPHISM
A. Importance of Pharmaceutical Solid Polymorphism
Polymorphic forms of a drug substance can have different chemical and physical properties, including melting point, chemical reactivity, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure, and density. These properties can have a direct effect on the ability to process and/or manufacture the drug substance and the drug product, as well as on drug product stability, dissolution, and bioavailability. Thus, polymorphism can affect the quality, safety, and efficacy of the drug product.

B. Characterization of Polymorphs
There are a number of methods that can be used to characterize polymorphs of a drug substance.11 Demonstration of a nonequivalent structure by single crystal X-ray diffraction is currently regarded as the definitive evidence of polymorphism. X-ray powder diffraction can also be used to provide unequivocal proof of polymorphism. Other methods, including microscopy, thermal analysis, and spectroscopy are helpful to further characterize polymorphic forms.

C. Influence of Polymorphism on Drug Substance and Drug Product

1. Influence on Solubility, Dissolution, and Bioavailability (BA) and Bioequivalence (BE):
The solid-state properties of a drug substance can have a significant influence on the apparent solubility of the drug substance. Since polymorphic forms differ in their internal solid-state structure, a drug substance that exists in various polymorphic forms can have different aqueous solubilities and dissolution rates. When there are differences in the apparent solubilities of the various polymorphic forms, we recommend that you focus on the potential effect such differences can have on drug product bioavailability (BA) and bioequivalence (BE).
Whether drug product BA/BE can be affected by the differences in apparent solubilities of the various polymorphic forms depends on the various physiological factors that govern the rate and extent of drug absorption including gastrointestinal motility, drug dissolution, and intestinal permeability. In this context, the Biopharmaceutics Classification System provides a useful scientific framework for regulatory decisions regarding drug substance polymorphism.
For a drug whose absorption is only limited by its dissolution, large differences in the apparent solubilities of the various polymorphic forms are likely to affect BA/BE. On the other hand, for a drug whose absorption is only limited by its intestinal permeability, differences in the apparent solubilities of the various polymorphic forms are less likely to affect BA/BE. Furthermore, when the apparent solubilities of the polymorphic forms are sufficiently high and drug dissolution is rapid in relation to gastric emptying, differences in the solubilities of the polymorphic forms are unlikely to affect BA/BE.
Upon demonstration of in-vivo bioequivalence between the generic drug product and the reference listed drug, in-vitro dissolution testing is then used to assess the lot-to-lot quality of the generic drug product. Drug product dissolution testing frequently provides a suitable means to identify and control the quality of the product from both the bioavailability and physical perspectives. In particular, inadvertent changes to the polymorphic form that may affect drug product BA/BE can often be detected by drug product dissolution testing.

2. Influence on Manufacturing of the Drug Product:
Drug substance polymorphic forms can also exhibit different physical and mechanical properties, including hygroscopicity, particle shape, density, flowability, and compactibility, which in turn may affect processing of the drug substance and/or manufacturing of the drug product. Since an ANDA applicant should demonstrate that the generic drug product can be manufactured reliably using a validated process, we recommend that you pay close attention to polymorphism as it relates to pharmaceutical processing.
The effect of polymorphism on pharmaceutical processing also depends on the formulation and the manufacturing process. For a drug product manufactured by direct compression, the solid-state properties of the active ingredient will likely be critical to the manufacture of the drug product, particularly when it constitutes the bulk of the tablet mass. On the other hand, for a drug product manufactured by wet granulation, the solid-state properties of the active ingredient are often masked by the resultant granulation, and the solid-state properties of the active ingredient are less likely to affect the manufacture of the drug product. In the context of the effect of polymorphism on pharmaceutical processing, what is most relevant is the ability to consistently manufacture a drug product that conforms to applicable in-process controls and release specifications.
Polymorphic forms of the drug substance can undergo phase conversion when exposed to a range of manufacturing processes, such as drying, milling, micronization, wet granulation, spray-drying, and compaction. Exposure to environmental conditions such as humidity and temperature can also induce polymorph conversion. The extent of conversion generally depends on the relative stability of the polymorphs, kinetic barriers to phase conversion, and applied stress. Nonetheless, phase conversion generally is not of serious concern, provided that the conversion occurs consistently, as a part of a validated manufacturing process where critical manufacturing process variables are well understood and controlled, and when drug product BA/BE has been demonstrated.

3. Influence on Stability:
Polymorphs can have different physical and chemical (reactivity) properties. The most thermodynamically stable polymorphic form of a drug substance is often chosen during development based on the minimal potential for conversion to another polymorphic form and on its greater chemical stability. However, a metastable form can be chosen for various reasons, including bioavailability enhancement. Since an ANDA applicant must demonstrate that the generic drug product exhibits adequate stability, we recommend that you focus on the potential effect that a polymorphic form can have on drug product stability. Nonetheless, because drug product stability is affected by a multitude of other factors, including formulation, manufacturing process, and packaging, it is the stability of the drug product and not stability of the drug substance polymorphic form that should be the most relevant measure of drug quality.
Polymorphic screening:

The step one of the ICH guideline is the polymorphism screening. Since polymorphism is to be considered for each salt candidate, it is not possible to separate salt selection and polymorphism selection. Different solid phases can be stable in different environments. For example in case of enantiotropy, at temperature below the transition point, the low melting form is the thermodynamic stable form. A hydrate can crystallize from aqueous solution and an anhydrous phase from organic solutions, both forms being stable in the context of crystallization. An anhydrous phase can be stable at low relative humidity and a hydrate at high relative humidity. But 'metastable' or 'unstable' forms may coexist resulting from supersaturation or from desolvation or dehydration. All possibilities have to be explored in a polymorphism screening. In organic chemistry, metastable forms may survive years if a considerable activation energy barrier has to be overcome in moving from the metastable state to the stable state. This activation-energy barrier may be reduced by moisture, catalysts, impurities, excipients, temperature and the transformation into the stable form occurs spontaneously. Seeds of the stable form may accelerate transformations. In the last step of synthesis, the temperature is generally lowered during crystallization. At the beginning of the crystallization the metastable form which is more soluble, may crystallize first, depending on the metastable zone of crystallization. Through solvent mediated transition the metastable form should be transformed into the stable form. But depending of the crystal growth and of the solubility, this transformation may not happen and the metastable form remains in the solid phase. In the case of hydrates, the water activity of the solvent or of the atmosphere is the key parameter for hydrate formation. The formation of solvates and hydrates is often the source of metastable anhydrous forms obtained during drying. The number of solid phases which may be correlated with a drug substance can be very high if one considers that a drug substance may form several solvates with each solvent.


Many examples show that in early development metastable forms or amorphous solids are first obtained and that during the development the unexpected thermodynamic stable form appears emphasizes the relevance of the discovery of a new highly insoluble form in a liquid formulation. Transformation of the metastable form into the insoluble form. By increasing the temperature, the 'apparent solubility' of the metastable form decreases since the transformation into the stable form is accelerated by the increase of temperature. All polymorphic screening procedures consider crystallizations and parameters such as temperature, co-precipitation, slurry in different solvents and in different conditions in order to explore the parameters of manufacture. High throughput this new form growths slowly from a liquid formulation. The new form was very insoluble and it was necessary to develop a new formulation in which the new form could be dissolved in the concentration needed for the therapy. The solubility of both crystalline forms was measured in a great number of liquid systems at different temperatures. Figure 1b illustrates the observed behavior of the solubility results, due to kinetic systems are now considered at drug discovery stage [27–29]. Quenching from the melt, lyophilization, precipitation by adding a co-solvent allow us to obtain the amorphous state. Heating/cooling curves in DSC or by combined techniques permit to observe forms which are not obtained from solvents.
The strategy of the screening should permit to:
• Obtain the drug candidate as crystalline form
• Detect solvate formation
• Manufacture ‘unstable’ or ‘metastable’ forms
• Study hydrate formation by water sorption-desorption experiments (Hygroscopicity)
• Consider solvate formation by adding solvent atmosphere studies to the crystallizations
• Manufacture amorphous phase.

No comments:

Post a Comment